Hormone therapy and risk of Alzheimer disease: A critical time

JAMA

Volumn 288, Issue 17, 2002, Pages 2170-2172

  Resnick, Susan M ^b   Henderson, Victor W ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GLUCOSE;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PROTECTION; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ESTROGEN THERAPY; GLUCOSE METABOLISM; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; NEUROBIOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 0037032405     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.17.2170     Document Type: Editorial

References (29)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288: 321-333.
2. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
3. Neuronal and Cognitive Effects of Oestrogens. Vol 230. Chichester, England: John Wiley & Sons, Ltd; 2000.
4. Maki PM, Resnick SM. Effects of estrogen on patterns of brain activity at rest and during cognitive activity: A review of neuroimaging studies. Neuroimage. 2001; 14:789-801.
5. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA. 1998;279: 688-695.
6. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
7. Zandi PP, Carlson MC, Plassman BL, et al, for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA. 2002;288:2123-2129.
8. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
9. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
10. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
11. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology. 1999;52:965-970.
12. Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm. Neurology. 1997;48:132-138.
13. Andersen K, Launer LJ, Dewey ME, et al, for the EURODEM Incidence Research Group. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. Neurology. 1999;53:1992-1997.
14. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study. Neurology. 2002;58:209-218.
15. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
16. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA. 2000;283:1007-1015.
17. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology. 2000;54:2061-2066.
18. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study. Am J Epidemiol. 1994;140:262-267.
19. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58:435-440.
20. Marder K, Sano M. Estrogen to treat Alzheimer's disease: Too little, too late? so what's a woman to do? Neurology. 2000;54:2035-2037.
21. Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive and brain aging. Ann N Y Acad Sci. 2001;949:203-214.
22. Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging. 2000;21:107-116.
23. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19: 604-621.
24. Vickers M. Collins N. Progress on the WISDOM trial-Women's International Study of Long Duration Oestrogen After Menopause. Climacteric. 2002;5 (suppl):133.
25. Sano M. Prevention of Alzheimer's disease: The problem of the drugs and the designs. Curr Neurol Neurosci Rep. 2002;2:392-399.
26. Toran-Allerand CD. Estrogen as a treatment for Alzheimer disease [letter]. JAMA. 2000;284:307-308.
27. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
28. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 1999;6:282-289.
29. Henderson VW, Klein BEK, Resnick SM. Menopause and disorders of neurologic function, mental health, and the eye. In: Wenger NK, Paoletti R, Lenfant CJM, Pinn VW, eds. International Position Paper on Women's Health and Menopause: A Comprehensive Approach. Vol 02-3284. Bethesda, Md: National Institutes of Health; 2002:251-270.